Fmr LLC lifted its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 0.0% in the 2nd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 220,043 shares of the specialty pharmaceutical company’s stock after purchasing an additional 43 shares during the quarter. Fmr LLC owned 0.75% of Collegium Pharmaceutical worth $2,753,000 as of its most recent filing with the SEC.

Several other large investors have also added to or reduced their stakes in the company. Credit Suisse AG grew its stake in shares of Collegium Pharmaceutical by 9.4% in the first quarter. Credit Suisse AG now owns 13,630 shares of the specialty pharmaceutical company’s stock worth $137,000 after purchasing an additional 1,173 shares in the last quarter. Nationwide Fund Advisors grew its stake in shares of Collegium Pharmaceutical by 16.4% in the first quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after purchasing an additional 1,422 shares in the last quarter. American International Group Inc. grew its stake in shares of Collegium Pharmaceutical by 27.8% in the first quarter. American International Group Inc. now owns 9,948 shares of the specialty pharmaceutical company’s stock worth $100,000 after purchasing an additional 2,163 shares in the last quarter. Bank of New York Mellon Corp grew its stake in shares of Collegium Pharmaceutical by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock worth $656,000 after purchasing an additional 3,775 shares in the last quarter. Finally, Geode Capital Management LLC grew its stake in shares of Collegium Pharmaceutical by 3.4% in the first quarter. Geode Capital Management LLC now owns 146,568 shares of the specialty pharmaceutical company’s stock worth $1,474,000 after purchasing an additional 4,866 shares in the last quarter. 83.25% of the stock is owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Collegium Pharmaceutical, Inc. (COLL) Stake Lifted by Fmr LLC” was originally posted by Watch List News and is owned by of Watch List News. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.watchlistnews.com/collegium-pharmaceutical-inc-coll-stake-lifted-by-fmr-llc/1684671.html.

Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) opened at $9.99 on Tuesday. Collegium Pharmaceutical, Inc. has a twelve month low of $7.37 and a twelve month high of $18.02.

Collegium Pharmaceutical (NASDAQ:COLL) last announced its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.81) by $0.09. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $4.07 million. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. equities analysts expect that Collegium Pharmaceutical, Inc. will post -3 EPS for the current fiscal year.

Several research analysts have recently issued reports on COLL shares. Zacks Investment Research cut Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Tuesday, July 11th. Piper Jaffray Companies set a $14.00 price target on Collegium Pharmaceutical and gave the stock a “buy” rating in a research note on Tuesday, July 25th. BidaskClub cut Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Friday, August 4th. HC Wainwright started coverage on Collegium Pharmaceutical in a research note on Monday, September 11th. They issued a “buy” rating and a $21.00 price target for the company. Finally, Jefferies Group LLC reissued a “buy” rating and issued a $15.00 price target on shares of Collegium Pharmaceutical in a research note on Thursday, September 21st. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus price target of $20.00.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL).

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.